VI. Endometriumkarzinom

REFERENZEN

Aslan D.L., Crapanzano J.P., Harshan M., Erroll M., Vakil B., Pirog E.C.: The Bethesda System 2001: recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007; 107 (1): 86–93

Baak J.P., Mutter G.L., Robbey Set al.: The molecular genetics and morphometry- based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103: 2304–12

Baek J.S., Lee W.H., Kang W.D., Kim S.M.: Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective? Obstet Gynecol Sci 2016; 59 (1): 24–31. doi: 10.5468/ogs.2016.59.1.24

Beal H.N., Stone J., Beckmann M.J., McAsey M.E.: Endometrial cells identified in cervical cytology in women > or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196 (6): 568.e1–5; discussion 568.e5–6

Ben-Arie A., Goldchmit C., Laviv Y., Levy R., Caspi B., Huszar M., Dani R., Hagay Z.: The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004; 115 (2): 206–210

Ben-Arie A., Tamir S., Dubnik S., Gemer O., Ben Sushan A., Dgani R., Peer G., Barnett-Griness O., Lavie O.: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008; 18 (4): 813–819

Blake P., Swart A.M., Orton J., Kitchener H., Whelan T., Lukka H., Eisenhauer E., Bacon M., Tu D., Parmar M.K., Armos C., Quian W. (ASTEC/ EN.5 Study Group): Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomized trials): polled trial results, systematic review, and meta analysis. Lancet 2009; 373 (9658): 137–46

Cochrane Database, Syst Rev 2000; (2): CD001040

Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C.; ESMOESGO- ESTRO Endometrial Consensus Conference Working Group: ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (1): 16–41

Courneya K.S., Karvinen K.H., Campbell K.L., Pearcey R.G., Dundas G., Capstick V. et al.: Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005; 97: 422–430

Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P. et al.: Carcinoma of the corpus uteri. J Epidemiol Biostat 2001; 6: 47–86

Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C., De Winter K.A., Lutgens L.C., van den Bergh A.C., van de Steen-Banasik E., Beerman H., van Lent M.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: a multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355 (9213): 1404–1411

Dijkhuizen F.P., Mol B.W., Brölman H.A., Heintz A.P.: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89: 1765–72

Egle D., Grissemann B., Zeimet A.G., Müller-Holzner E., Marth C.: Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma. Gynecol Oncol 2008; 110 (3): 286–92

Ferguson S.E. et al.: Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101: 322–326

Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., Kline R., Burger R.A., Goodman A., Burks R.T.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22 (11): 2159–2166

Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., Gallion H.: Phase III rancomized trial of doxorubicin plus cisplatin versus doxorubicin plus 24 h paclitaxel plus filgastrim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 2004; 15 (8): 1173–1178

Fotopoulou C., Kraetschell R., Dowdy S., Fujiwara K., Yaegashi N., Larusso D., Casado A., Mahner S., Herzog T.J., Kehoe S., Vergote I., Miller D.S., Marth C., Fujii S., Sehouli J.: Surgical and systemic management of endometrial cancer: an international survey. Arch Gynecol Obstet 2015; 291 (4): 897–905

Franchi M., Ghezzi F., Melpignano M. et al.: Clinical value of intraoperative gross examination in endometrial cancer. Gynecol Oncol 2000; 76: 357–63

Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207 (4): 266.e1–12. doi: 10.1016/j.ajog.2012.08.011

Gehrig P.A., Van Le L., Olatidoye B., Geradts J.: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86 (10): 2083–2089

Gull B., Carlsson S., Karlsson B., Ylöstalo P., Milsom I., Granberg S.: Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000; 182 (3): 509–515

Havrilesky L.J., Cragun L.M., Calingaert B., Alvarez Secord A., Valea F.A., Clarke-Pearson D.L, Berchuck A., Soper J.T.: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007; 104 (2): 401–405

Hogberg T., Rosenberg P., Kristensen G. et al.: A randomized phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9505/EORTC 55991). J Clin Oncol 2007; 25: 247s

Hogberg T.: Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 2008; 20 (6): 463–9

Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., Green J.A.: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane Collaboration. Ann Oncol 2007; 18 (3): 409–420

Johnson N., Cornes P.: Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and metaanalysis. BJOG 2007; 114: 1313–20

Kong A. et al., Cochrane Database Syst Rev 2007; (2): CD003916

Kurman R.J., Kaminski P.F., Norris H.J.: The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. CA Cancer J Clin 1985; 56: 403–12

Kwon J.S., Francis J.A., Qiu F. et al.: When is a pathology review indicated in endometrial cancer? Obstet Gynecol 2007; 110: 1224

Lacey J.V. Jr., Sherman M.E., Rush B.B. et al.: Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28: 788–92

Lambrou N.C., Gomez-Martin O., Mirhashemi R., Beach H., Salom E., Almeida-Parra Z., Penalver M.: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004; 93 (3): 653–58

Leitao M.M. Jr., Kehoe S., Barakat R.R. et al.: Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2008; 111: 244–48

Lindauer J., Fowler L.M., Manolitsas T.P., Copeland L.J., Eaton L.A., Ramirez N.C., Crohn D.E.: Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? Gynecol Oncol 2003; 91 (3): 547–551

May K., Bryant A., Dickinson H.O., Kehoe S., Morrison J.: Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007585. DOI: 10.1002/14651858.CD007585.pub2

Miller D., Filiaci V., Fleming G., Mannel R., Cohn D., Matsumoto T. et al.: Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771

Nout R.A., Smit V.T., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Mens J.W., Slot A., Froese M.C., van Bunningen B.N., Ansink A.C., van Putten W.L., Creutzberg C.L.; PORTEC Study Group: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375 (9717): 816–23

Parslov M., Lifegaard Ø., Klintrop S., Pedersen B., Jønsson L., Eriksen P. S., Ottesen B.: Risk factors among young women with endometrial cancer: A Danish case-control study. Am J Obstet Gynecol 2000; 182: 23–29

Pecorelli S.: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol and Obstet 2009; 105: 103–104

Pristauz G., Bader A.A., Regitnig P., Haas J., Winter R., Tamussino K.: How accurate is frozen section histology of pelvic lymph nodes in patients with endometrial cancer? Gynecol Oncol 2009; 115 (1): 12–17

Randall M.E., Spirtos N.M., Dvoretsky P.: Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr 1995; 19: 13–5

Ronnett B.M., Kurman R.J.: Precursor Lesions of Endometrial Carcinoma. In: Blausteins Pathology of the female genital tract. Editor: Robert J.Kurman, Fifth Edition 2002, Springer Verlag, New York, Berlin, Heidelberg

Silverman M.B., Roche P.C., Kho R.M., Keeney G.L., Li H., Podratz K.C.: Molecular and cytokinetic pretreatment risk in endometrial carcinoma. Gynecol Oncol 2000; 77 (1): 1–7

Smith-Bindman R., Weiss R., Feldstein V.: How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24: 558

Statistik Austria, Österreichisches Krebsregister (Stand: Stand 02.10.2015)

Thipgen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 1; 22 (19): 3902–3908

Timmermans A., Opmeer B.C., Khan K.S. et al.: Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 160–67

Trimble C.L., Kauderer J., Zaino R., Silverberg S., Lim P.C., Burke J.J.2nd, Alberts D., Curtin J.: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006 Feb; 106: 812–819

Watanabe Y., Satou T., Nakai H., Etoh T., Dote K., Fujinami N., Hoshiai H.: Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116 (5): 1027–34

Wright T.C. Jr., Massad S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., for the 2006 American society for Colposcopy and Cervical Pathology – sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. Am J Obstet Gynecol 2007 Oct; 346–355

Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., Abdel-Azim S., Müller-Holzner E., Ben-Arie A., van Kempen L.C., Petru E. et al.: L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013; 105: 1142-1150